免疫疗法
对偶（语法数字）
计算生物学
癌症免疫疗法
癌症研究
医学
标识
DOI：10.1158/2159-8290.cd-nb2022-0008
摘要
In the phase III HIMALAYA trial, a single priming dose of tremelimumab plus once-monthly durvalumab was associated with better overall survival compared with sorafenib as first-line treatment for patients with inoperable hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
浮游
猪猪hero
GingerF
yyds
VDC
ceeray23
ruopiao
无极微光
GPTea
yznfly
月下独酌42
走啊走
lucky
大龙哥886
zyx
zzzgk
freyaaaaa
冯宇
jacky1
子车茗
fei
小蘑菇
Kapur
blackddl
皖公网安备34019202002308
